BridgeBio Pharma, Inc.
On May 28, analysts adjusted price targets across multiple stocks. Agilent’s target was cut by Wells Fargo ($165→$160) but raised by Barclays ($140→$145) and TD Cowen ($147→$155). Affirm’s target rose at Truist ($75→$80). Bath & Body Works saw mixed changes, while Salesforce targets were mostly lowered by several firms.
Morgan Stanley raised its price target for BridgeBio Pharma (BBIO) to $98 from $94 and kept an “overweight” rating, citing potential upside of 47.81% versus the prior close, according to Benzinga. Other analysts cited include Citigroup ($82, neutral) and Wells Fargo ($98, overweight). BBIO last reported May 7 EPS of -$0.84 and revenue of $194.52M.
HC Wainwright reiterated a “Buy” rating on BridgeBio Pharma (NASDAQ:BBIO) and set a $110.00 price target, implying 65.56% upside from the current price, according to Benzinga. The article also cites other analysts’ targets ranging from $94 to $102. BBIO reported Q1 EPS of ($0.84) and revenue of $194.52M.
